Eur Heart J:稳定性冠心病患者血压应<140/80 mmHg

2018-08-26 朱柳媛 中国循环杂志

2017年美国高血压新指南发布至今,争议不断。其一是将高血压重新定义,即将平均收缩压>130 mmHg或舒张压>80 mmHg作为高血压诊断标准,此前相应的标准是140/90 mmHg。更有争议的是,只要血压>130/80 mmHg,该指南都建议接受降压治疗。根据这个新指南,收缩压处于130~139mmHg或舒张压80~89 mmHg的冠心病患者都要服用降压药物,而这部分人按照既

2017年美国高血压指南发布至今,争议不断。其一是将高血压重新定义,即将平均收缩压>130 mmHg或舒张压>80 mmHg作为高血压诊断标准,此前相应的标准是140/90 mmHg。更有争议的是,只要血压>130/80 mmHg,该指南都建议接受降压治疗。

根据这个新指南,收缩压处于130~139mmHg或舒张压80~89 mmHg的冠心病患者都要服用降压药物,而这部分人按照既往标准为血压正常人群。

那么,这一推荐是否有证据呢?我们从近期发表在欧洲心脏杂志上的CLARIFY注册登记研究结果或许能得到一些答案。

这项来自真实世界的国际性研究表明,对于稳定性冠心病患者,舒张压80~89 mmHg与血管风险增加有关,而收缩压130~139 mmHg并不增加血管风险。这提示,稳定性冠心病患者舒张压要稍微降得再低一点,而收缩压应仍以<140 mmHg而非<130/80 mmHg为目标。

分析显示,与舒张压处于70~79 mmHg的患者相比,舒张压80~89mmHg的患者发生心脑血管疾病(包括心血管死亡、心肌梗死和脑卒中)的风险增加1.15倍。

然而,与收缩压120~129 mmHg的患者相比,收缩压130~139mmHg的患者发生心脑血管疾病的风险未显著增加(HR=1.12,95% CI:0.64-1.97),收缩压<120 mmHg的患者罹患上述事件的风险也未增加(HR=1.16,95% CI:0.65–2.05)。



不同收缩压和舒张压水平对应的心血管风险
收缩压以120~129 mmHg、舒张压以70~79mmHg为参照)

交互分析显示,收缩压和舒张压对心脑血管事件风险的影响不存在相互作用。换句话说,不论患者收缩压水平如何,只要舒张压处于80~89 mmHg,心脑血管事件发生风险都会增加。

研究者指出,该研究的数据并不支持收缩压处于130~139mmHg的患者启动降压治疗,如果这类患者正服用有降压作用的抗心绞痛药物,也不支持他们强化降压。

当然,该研究仅为观察性研究,很多患者的血压值是偶然诊室血压检查结果,且该研究由于样本量较小,所以上述结果还有待于进一步验证。

CLARIFY研究是一项前瞻性、观察性、纵向注册登记研究,覆盖全球45个国家,共纳入32 703例稳定性冠心病患者。

这项新分析纳入其中的5969例无高血压病史(平均血压<140/90mmHg)的稳定性冠心病患者,中位随访5年。受试者中位年龄61岁,其中17%有糖尿病,平均收缩压和舒张压分别为122.7 mmHg和74.1 mmHg。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900485, encodeId=40311900485f9, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Oct 04 21:48:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356903, encodeId=aa63135690395, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447730, encodeId=ffba144e730d8, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562961, encodeId=0d7b156296195, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1900485, encodeId=40311900485f9, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Oct 04 21:48:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356903, encodeId=aa63135690395, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447730, encodeId=ffba144e730d8, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562961, encodeId=0d7b156296195, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-28 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1900485, encodeId=40311900485f9, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Oct 04 21:48:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356903, encodeId=aa63135690395, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447730, encodeId=ffba144e730d8, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562961, encodeId=0d7b156296195, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1900485, encodeId=40311900485f9, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Oct 04 21:48:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356903, encodeId=aa63135690395, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447730, encodeId=ffba144e730d8, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562961, encodeId=0d7b156296195, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Aug 28 09:48:00 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-28 slcumt

相关资讯

JACC:冠心病的生物标志物筛选

寻找引起冠心病(CAD)的生物标志物对其防治有重要意义。本研究的目的旨在通过孟德尔随机分析(MR)在237个生物标志物中筛选出引起CAD的生物标志物。本研究对ORIGIN临床研究中的4147名研究对象进行227个生物标志物的遗传决定性MR分析,并结合CARDIoGRAM团队(60801例病人和123504例对照)中的CAD分析结果。经多假设检验调整后发现,有6个生物标志物与CAD建立了相关性,其中

JACC:稳定性冠心病患者应不应该接受介入治疗?

最近,经皮冠脉介入治疗(PCI)的治疗效益在稳定性冠心病(SCD)患者中存在争议。本研究的目的旨在评估PCI对SCD患者锻炼后的冠脉循环、微循环和全身血液动力学的影响。本研究对21例SCD伴单支冠脉狭窄的患者(平均年龄60.3 ± 8.4岁)进行了心导管术。PCI术前,患者在仰卧测力计上运动直至心绞痛或筋疲力尽,在运动的同时对狭窄的冠脉血流进行测量,PCI术后同样做此操作,并比较术前和术后患者的生

Circulation:冠心病患者从替格瑞洛降阶梯到氯吡格雷后…

2018年6月,发表在《Circulation》的一项前瞻性、随机、开放标签研究,考察了冠心病患者从替格瑞洛降阶梯到氯吡格雷后,是否与血小板反应性增加相关。

Circulation:D-二聚体水平可预测冠心病患者的长期死亡率、心血管事件和癌症发病率

D-二聚体是交联纤维蛋白的降解产物,是高凝和血栓形成的标志物。D-二聚体中度升高与血管疾病患者的动静脉事件的风险相关。现研究人员对D-二聚体水平用于预测长期血管预后、特殊原因的死亡率以及新发癌症的作用进行评估。LIPID试验,将心肌梗死或不稳定心绞痛发生后5-38个月的患者随机分至普伐他汀(40mg/d)或安慰剂组。于起始和1年时检测D-二聚体水平。中位随访6.0年,总起来16年。7863位患者按

“中国标准”诊“心病”

“心病”难治。中国有约1300万名冠心病患者,仅去年一年就有约75.3万人接受了冠状动脉介入手术,更有大约超过300万人接受了冠脉造影检查。

Circulation:观点文章:应对心血管病“达摩克里斯之剑”,葛均波院士开出五个处方

7月24日,Circulation杂志葛均波院士观点文章。文章称,心血管病“达摩克利斯之剑”正悬在中国人民头上。